

February 2, 2022

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051.

Subject: Newspaper Publication of Financial Results.

Dear Sir/Madam,

Please find attached newspaper publication of financial results for the quarter ended December 31, 2022, published in the Business Standard Mumbai on February 2, 2022.

Kindly take the same on your record and acknowledge.

Thanking You, FOR NIIF Infrastructure Finance Limited

Ankit Sheth Company Secretary

Encl: As above

Т	TP SOUTHERN ODISHA DISTRIBUTION LIMITED (Procurement Department) Call Center/Training Center, Duduma Colony, Ambagada, Berhampur, Odisha-760001							
NOTICE INVITING TENDER Date: 02.02.2023 TP Southern Odisha Distribution Limited (TPSODL) invites tender from eligible vendors for following: Date: 02.02.2023								
SI. Tender Description NIT Number EMD (Rs. Lakh) Tender Fee Last date inclusive of time of Pa								
1.	Procurement of VMWare cloud suite standard 2019 & Support for 01 year.		0.50	5,000/-	13.02.2023 17:00 Hrs			
2.	Microsoft SQL Server Enterprise 02 Core License with Warranty Support of 3 years SITC and training of On Prem Microsoft Exchange Server & User CAL with Warranty Support of 1 year	TPSODL/OT/	1.00	5,000/-	13.02.2023 17:00 Hrs			
	For detailed tender, please https://ww	e visit Tender w.tpsouther			website			

Small Industries development Bank of India						
GeM Bid NOTICE						
SIDBI invites eligible bidders to submit bids in GeM Portal for following bids:						
Bid Description	GeM Bid Reference No.					
Procurement of managed extended detection and response solution	GEM/2023/B/3042419 dated 02/02/2023					
For detailed bid document, please visit GeM Portal (gem.gov.in) or our website at www.sidbi.in. Addendum/ Corrigendum, if any, will be published in the above- mentioned websites only.						

बो पाम क लि BP\$CL	(A Joint Vent Hall No. : M-01, Old Ispat Bhavan, Bokaro S CIN No. : U403	Supply Co. (P) Ltd. ure of SAIL & DVC) 4 Administrative Building Steel City-827001(Jharkhand) 00DL2001PTC112074
	NOTICE INVITING EXPRESS	ON OF INTEREST
Ref. No. : BPSCL	/MM/22-23/EOI-003/188	Date : 28.01.2023
BPSCL invites Ex	pression of Interest (EOI) for Reva	amping, Testing & Commissioning of
	hase pneumatic Ash Handling P	· · · · · · · · · · · · · · · · · · ·
EOI is available amendments, time separate notification	at our website www.bpscl.cor e extensions etc., if any, will also	n / etenders.gov.in . All corrigenda, be published in the same website. No he applicants are requested to regularly
Last date & time f	or submission of EOI : 14.03.2023	(12.00 Noon).
		For and on behalf of BPSCL
		(A. K. Das)
		CGM (MM)

15

Balaxi Pharmaceuticals Limited

Registered Office: Plot No.409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598 | Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in


EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS

~			STANDALO	NE		CONSOLIDATED			
SI. No.	Particulars	Quarter ended 31/12/2022 Unaudited	Nine Months ended 31/12/2022 Unaudited	Quarter ended 31/12/2021 Unaudited	Quarter ended 31/12/2022 Unaudited	Nine Months ended 31/12/2022 Unaudited	Quarter 31/12/2 Unauc		
1.	Total Income from Operations	2,306.81	7,778.64	1,795.3	8,658.17	25,575.14	6,17		
2.	Net profit/(loss) for the period (before tax, exceptional and/or extraordinary items)	481.15	1,726.81	327.58	1,052.57	4,585.4	1,29		
3.	Net profit/(loss) for the period before tax (after exceptional and/or extraordinary items)	481.15	1,726.81	327.58	1,052.57	4,585.4	1,29		
4.	Net profit/(loss) for the period after tax (after exceptional and/or extraordinary items)	353.14	1,284.33	247.39	822.89	3,786.23	1,21		
5.	Total Comprehensive Income for the period [Comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	353.14	1,284.33	247.39	846.92	4,382.9	1,22		
6.	Paid-up Equity Share Capital [Face value of Rs. 10 each]	1,002.45	1,002.45	1,000.00	1,002.45	1,002.45	1,00		
7.	Reserves (excluding Revaluation Reserve) as per the Audited Balance Sheet of the previous year			4,791.30					
8.	Earnings Per Share (of Rs.10/- each) (not annualised)								
Note	1. Basic (amount in Rs.) 2. Diluted (amount in Rs.)	3.52 3.44	12.83 12.74	2.47 2.47	8.21 8.03	37.83 37.55	1 1		

31st January, 2023 and 01st February,2023, respectively. The said Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.

For and on behalf of Board of Directors. Balaxi Pharmaceuticals Limited Ashish Maheshwari

Mana	agin	ıу с	mec	loi
DIN	1: 0	157	5984	4



RPG LIFE SCIENCES An %>RPG Company							
RPG LIFE SCIENCES LIMITED							
	Regd. Office: RPG House, 463, Dr. Annie	Besant Road	d. Worli. Mum	bai 400 030.			
	CIN: L24232MH20			100 000.			
	Tel: +91-22-2498 1650; F		.,				
	E-mail: info@rpglifesciences.com;						
		•	<u> </u>				
	Extract of Standalone Unaudited Financial Results for th	e Quarter an	nd Nine Mont	ths ended D	ecember 31,	2022	
					(F	Rs. in Lakł	
Quarter ended Nine months ended Year ende							
	Particulars	Dec 31, 2022 (Unaudited)	Dec 31, 2021 (Unaudited)	Dec 31, 2022 (Unaudited)	Dec 31, 2021 (Unaudited)	March 3 2022 (Audited	
1	Total Income from Operations	13,060	11.558	39,432	33.636	44,0	
	Net Profit for the period (before tax, exceptional and extraordinary items)	2,574	2.062	7,787	6,224	7,3	
			0,000	7.787	6,224	7,3	
2	Net Profit for the period before tax (after exceptional and extraordinary items)	2,574	2,062				
	Net Profit for the period before tax (after exceptional and extraordinary items) Net Profit for the period after tax (after Exceptional and Extraordinary items)	2,574 1,911	2,062	5,729	4,396	5,1	
	Net Profit for the period before tax (after exceptional and extraordinary items)	,	,	. ,	4,396 4,387	5,1	
	Net Profit for the period before tax (after exceptional and extraordinary items) Net Profit for the period after tax (after Exceptional and Extraordinary items) Total Comprehensive Income for the period [Comprising Profit for the period	1,911	1,463	5,729	.,	5,1	
	Net Profit for the period before tax (after exceptional and extraordinary items) Net Profit for the period after tax (after Exceptional and Extraordinary items) Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	1,911	1,463 1,460	5,729 5,709	4,387	5,7	
	Net Profit for the period before tax (after exceptional and extraordinary items) Net Profit for the period after tax (after Exceptional and Extraordinary items) Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)] Paid-up equity share capital (Face Value Rs.8/- each) Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of the previous year	1,911	1,463 1,460	5,729 5,709	4,387	5,1 1,3	
	Net Profit for the period before tax (after exceptional and extraordinary items) Net Profit for the period after tax (after Exceptional and Extraordinary items) Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)] Paid-up equity share capital (Face Value Rs.8/- each) Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of the previous year Earnings Per Share (Rs.8/- each) - (not annualised for the quarter):	1,911 1,905 1,323 -	1,463 1,460 1,323 -	5,729 5,709 1,323 -	4,387 1,323 -	5,1 1,3 24,2	
2 3 4 5 7	Net Profit for the period before tax (after exceptional and extraordinary items) Net Profit for the period after tax (after Exceptional and Extraordinary items) Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)] Paid-up equity share capital (Face Value Rs.8/- each) Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of the previous year	1,911	1,463 1,460	5,729 5,709	4,387	5, 1,	

The Company operates in only one reportable business segment i.e. Pharmaceuticals.

The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results filed with the Stock Exchange websites viz. (www.nseindia.com and www.bseindia.com) and on Company's website (www.rpglifesciences.com)

For RPG Life Sciences Limited Yugal Sikri

Managing Director

DIN:07576560

Place: Hyderabad

Date: 01st February, 2023

Date : February 01, 2023 Place : Mumbai

	NIIF IFL INFRASTRUCTURE FINANCING NIIF Infrastructure Finance Limited							
	("Formerly IDFC Infrastructure Finance Limited")							
	Registered Office: North Wing, 3 ^{ed} Floor, UTI Tower, GN Block, Bandra Kurla Complex, Mumbai - 400 051, Maharashtra. CIN No: U67190MH2014PLC253944 Website: www.niififl.in Tel. No: +91 22 68591300.							
	Statement of unaudited financial results for the nine month ended December 31, 2022							
	(₹ in crore)							
Sr. No.	Particulars	Nine Months ended December 31, 2022	Nine Months ended December 31, 2021	Year ended March 31, 2022				
		(Unaudited)	(Unaudited)	(Audited)				

1	Total Income from Operations	1,033.02	697.94	977.19
2	Net Profit /(Loss) for the period (before tax, Exceptional and/or Extraordinary items)	240.22	178.05	233.25
3	Net Profit /(Loss) for the period before tax (after exceptional and/or Extraordinary items)	240.22	178.05	233.25
4	Net Profit /(Loss) for the period after tax (after exceptional and/or Extraordinary items)	240.22	178.05	233.25
5	Total Comprehensive Income for the period [comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	239.25	178.32	233.10
6	Paid-up equity share capital including redeemable preference shares	1,909.02	1,100.38	1,909.02
7	Reserves (excluding revaluation reserves)	1,445.16	947.92	1,205.92
8	Securities Premium Account	547.59	344.37	547.59
9	Net Worth	3,354.18	2,048.30	3,114.94
10	Paid-up Debt Capital/Outstanding Debt	14,360.50	9,634.61	12,322.74
11	Outstanding Redeemable Preference Shares	Nil	Nil	Nil
12	Debt Equity Ratio	4.28	4.70	3.96
13	Earnings per share (of ₹ 10 each) (for continuing and discontinuing operations) (not annualised)			
	Basic (₹)	1.75	1.78	2.31
	Diluted (₹)	1.75	1.78	2.31
14	Capital Redemption Reserve/Debenture Redemption Reserve	Nil	Nil	Nil
15	Debenture Redemption Reserve	Nil	Nil	Nil

Notes:

1. The above is an extract of detailed format of Nine Month ended financials results filed with the Stock Exchange under Regulation 52 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The full format of the yearly financial results is available on www.nseindia.com & www.niififl.in. The above financial results of the Company have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 ("Ind AS") prescribed under Section 133 of the Companies Act, 2013. The Company has adopted Ind AS from April 1, 2018 with a transition date of April 1, 2017.

2 The aforesaid financial results of the Company were reviewed by the Audit Committee on January 31, 2023 and approved by the Board of Directors at its meeting held on February 1, 2023.

3 The debentures of the Company have been assigned rating of "AAA" by ICRA Limited & CARE Ratings Limited.

4 The figures for previous period/year have been regrouped wherever required, to correspond with those of the current period/year.

For and on behalf of the Board of NIIF Infrastructure Finance Limited

ace: Mumbai		Chairr
Ratios	Description	December 31, 202
Debt-Equity Ratio	Total Debt / Total Equity	4.28
Current Ratio	NA	NA
Long Term Debt to Working Capital	NA	NA
Bad Debts to Account Receivable Ratio	NA	NA
Current Liability Ratio	NA	NA
Total Debts to Total Assets	Total Debt / Total Asset	0.81
Debtors Turnover	NA	NA
Inventory Turnover	NA	NA
Operating Margin (%)	Operating Profit / Total Revenue	23.15%
Net Profit Margin (%)	PAT / Total Revenue	23.16%
Net Worth (₹ in Crore)	Share capital + Reserves and surplus	3,354.18
Net Profit After Tax (₹ in Crore)		239.25
Earnings Per Share (Basic)	PAT / Total number of shares	1.75
Earnings Per Share (Diluted)	PAT / Total diluted number of shares	1.75
Gross/ Net Non-Performing Assets (NPAs)		Nil
Capital Redemption Reserve/Debenture Redemption Reserve*	NA	NA

items, before share of profit of joint ventures and						
associate and tax	625	676	312	2,069	952	1,441
4. Profit from continuing operations before tax	534	723	406	2,054	1,154	1,667
5. Profit from continuing operations after tax	432	685	340	1,758	930	1,400
6. (Loss)/profit from discontinued operations before tax	(7)	(5)	10	(16)	37	18
7. (Loss)/profit from discontinued operations after tax	(7)	(5)	10	(16)	30	5
8. Profit for the period (5 + 7)	425	680	350	1,742	960	1,405
9. Total comprehensive income for the period	139	1,543	743	1,494	3,173	4,364
10. Paid-up equity share capital (Face value: ₹ 10 per share)	255	255	255	255	255	255
11. Other equity and Non-controlling interests						18,902
12. Earnings per share						
- Basic and Diluted (for continuing operations) in ₹	15.62*	24.85*	11.82*	63.75*	31.00*	49.17
- Basic and Diluted (for discontinued operations) in ₹	(0.27)*	(0.20)*	0.37*	(0.63)*	1.17*	0.20
- Basic and Diluted (for continuing and discontinued						
operations) in ₹	15.35*	24.65*	12.19*	63.12*	32.17*	49.37
* Not annualised						

Extracts of Statement of Standalone Audited Financial Results for the quarter and nine months ended 31 December, 2022

						(₹ in crore)
Particulars	Quarter ended 31 December, 2022	Quarter ended 30 September, 2022	Quarter ended 31 December, 2021	Nine months ended 31 December, 2022	Nine months ended 31 December, 2021	Year ended 31 March, 2022
1. Revenue from continuing operations	1,218	1,185	931	3,628	2,606	3,721
2. Profit from continuing operations before tax	244	277	213	1,016	672	988
3. Profit from continuing operations after tax	190	243	155	814	518	787
4. Profit from discontinued operations before tax	-	-	-	-	27	28
5. Profit from discontinued operations after tax	-	-	-	-	20	15
6. Profit for the period (3 + 5)	190	243	155	814	538	802
7. Total comprehensive income for the period	194	1,279	578	989	1,901	2,340
8. Paid-up equity share capital (Face value: ₹ 10 per share)	255	255	255	255	255	255
9. Other equity						15,088
10. Earnings per share						
- Basic and Diluted (for continuing operations) in ₹	7.46*	9.54*	6.11*	31.95*	20.35*	30.87
- Basic and Diluted (for discontinued operations) in ₹	-	-	-	-	0.80*	0.59
 Basic and Diluted (for continuing and discontinued operations) in ₹ * Not annualised 	7.46*	9.54*	6.11*	31.95*	21.15*	31.46

Notes:

1 The above is an extract of the detailed format of the Unaudited Consolidated and Audited Standalone financial results for the quarter and nine months ended 31 December, 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Consolidated and Audited Standalone financial results for the quarter and nine months ended 31 December, 2022 is available on the Stock Exchange websites (www.nseindia.com and www.bseindia.com) and on the Company's website (www.tatachemicals.com).

2. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 1 February, 2023.

> For and on behalf of the Board of TATA CHEMICALS LIMITED

Place : Mumbai Date : 1 February, 2023

R. Mukundan Managing Director and CEO

TATA CHEMICALS LIMITED

Regd. Office : Bombay House, 24, Homi Mody Street, Fort, Mumbai - 400 001. Tel: +91 22 66658282 Website: www.tatachemicals.com CIN:- L24239MH1939PLC002893 Email: investors@tatachemicals.com